PerkinElmer Launches VICTOR(R) Nivo(TM) Multimode Plate Reader

Food and Healthcare Press Releases Tuesday July 25, 2017 10:09
WALTHAM, Mass.--25 Jul--PRNewswire/InfoQuest
Multiple Detection Modes and Intuitive Software Help to Simplify and Accelerate Disease Research and Drug Discovery

PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, announced on July 24 (US-time) the launch of its new VICTOR(R) Nivo(TM) multimode plate reader . Designed to fit almost any lab space, this compact, lightweight instrument provides high performance detection modes and easy-to-use software, which allows scientists to be able to accelerate biochemical and cell-based assays for disease research and drug development.

For the full multimedia release, click here: http://www.prnasia.com/mnr/perkinelmer_201707.shtml
https://photos.prnasia.com/prnvar/20170724/1903341-1-a
https://photos.prnasia.com/prnvar/20170724/1903341-1-b
https://photos.prnasia.com/prnvar/20170724/1903341-1-c

"In today's academic and pharmaceutical labs, scientists need intuitive, high performance technologies, including multimode microplate readers,   that can be applied to a broad range of applications to help advance their research," said Jim Corbett, Executive Vice President and President, Discovery & Analytical Solutions, PerkinElmer. "We offer a complete set of innovative solutions that are designed to help facilitate scientific breakthroughs."

"Multimode detection is an integral process in helping to advance our research," said Maria Kuzikov, Assay Development and Screening Specialist, Fraunhofer IME Screening Port in Germany, a PerkinElmer customer. "We have found that the VICTOR(R) Nivo(TM) multimode plate reader provides high performance for a broad range of biochemical and cell based applications including measuring cell proliferation and cytotoxicity, DNA and protein quantification, as well as characterization of compound effects on PDE activity. The reader is very easy to use so that even beginners can become productive quickly."

With a wide range of key detection modes, top and bottom reading for all modes and space for up to 32 filters, the instrument delivers high performance for cell-based and biochemical assays and can accommodate multiple users and applications. Its small, compact design helps researchers to maximize their lab resources, freeing up valuable bench space for other activities critical to the research process.

Scientists can control the instrument's software via Wi-Fi or network connection from a PC, laptop or tablet in order to effectively manage their workflows. The software's user interface makes it easy for novice scientists to quickly learn and navigate the instrument.

PerkinElmer offers a comprehensive portfolio of technologies to support life science research, including assay reagents, microplates, liquid handling/automation, and services. To learn more about the VICTOR Nivo multimode plate reader, visit www.perkinelmer.com/Nivo .

ABOUT PERKINELMER:

PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. Our dedicated team of 9,000 employees worldwide are passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the diagnostics, discovery and analytical solutions markets. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us.   The Company reported revenue of approximately $2.1 billion in 2016, serves customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com .

Follow us on Twitter @PKILifeScience .
Contact:
Samantha Pierce
+1-585-697-2606
perkinelmerdas@apcoworldwide.com

Latest Press Release

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

NovoEight(R) Maintains Potency When Stored at 40?C Offering People With Haemophilia A Increased Flexibility in Their Daily Lives

A new long term stability study has shown that haemophilia A treatment NovoEight(R) (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow,...

Related Topics